These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 4609344)

  • 1. Bioavailability of diphenylhydantoin.
    Albert KS; Sakmar E; Hallmark MR; Weidler DJ; Wagner JG
    Clin Pharmacol Ther; 1974 Oct; 16(4):727-35. PubMed ID: 4609344
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma level studies on different brands of sodium diphenylhydantoin (DPH) and primidone.
    Borst SI; Lockwood CH
    Int J Clin Pharmacol Biopharm; 1975 Oct; 12(3):309-14. PubMed ID: 1242131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability and dissolution of proprietary and generic formulations of phenytoin.
    Soryal I; Richens A
    J Neurol Neurosurg Psychiatry; 1992 Aug; 55(8):688-91. PubMed ID: 1527539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of phenytoin availability from pharmaceutical preparations].
    Leucuţa SE; Almaşu I
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1986; 31(4):273-82. PubMed ID: 2951832
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma diphenylhydantoin levels in Australian adults.
    Hooper WD; Tyrer JH; Eadie MJ
    Aust N Z J Med; 1974 Oct; 4(5):449-55. PubMed ID: 4532913
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin.
    Kostenbauder HB; Rapp RP; McGovren JP; Foster TS; Perrier DG; Blacker HM; Hulon WC; Kinkel AW
    Clin Pharmacol Ther; 1975 Oct; 18(4):449-56. PubMed ID: 1100308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of plasma protein binding of diphenylhydantoin.
    Baggot JD; Davis LE
    Comp Gen Pharmacol; 1973 Dec; 4(16):399-404. PubMed ID: 4788790
    [No Abstract]   [Full Text] [Related]  

  • 8. Bioavailability of phenytoin: a comparison between two preparations.
    Zylber-Katz E; Granit L; Levy M
    Isr J Med Sci; 1978 Apr; 14(4):489-91. PubMed ID: 352994
    [No Abstract]   [Full Text] [Related]  

  • 9. Diphenylhydantoin potency and plasma protein binding.
    Shoeman DW; Azarnoff DL
    J Pharmacol Exp Ther; 1975 Oct; 195(1):84-6. PubMed ID: 1181407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.
    Booker HE; Darcey B
    Epilepsia; 1973 Jun; 14(2):177-84. PubMed ID: 4515987
    [No Abstract]   [Full Text] [Related]  

  • 11. A method for shifting from oral to intramuscular diphenylhydantoin administration.
    Wilder BJ; Serrano EE; Ramsey E; Buchanan RA
    Clin Pharmacol Ther; 1974 Sep; 16(3):507-13. PubMed ID: 4411662
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of protein binding on the distribution of 5,5-diphenylhydantoin between plasma and red cells.
    Borondy P; Dill WA; Chang T; Buchanan RA; Glazko AJ
    Ann N Y Acad Sci; 1973 Nov; 226():82-7. PubMed ID: 4520405
    [No Abstract]   [Full Text] [Related]  

  • 13. Microultrafiltration technique for drug-protein binding determination in plasma.
    Shah VP; Wallace SM; Riegelman S
    J Pharm Sci; 1974 Sep; 63(9):1364-7. PubMed ID: 4427256
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications.
    Neuvonen PJ
    Clin Pharmacokinet; 1979; 4(2):91-103. PubMed ID: 378503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentrations of orally administered diphenylhydantoin in dogs.
    Sanders JE; Yeary RA
    J Am Vet Med Assoc; 1978 Jan; 172(2):153-6. PubMed ID: 758073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phenytoin pharmacokinetics as a function of the preparation: capsules, commercial tablets and experimental tablets].
    Almaşu I; Leucuţa SE
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1986; 31(4):283-93. PubMed ID: 2951833
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease.
    Hooper WD; Bochner F; Eadie MJ; Tyrer JH
    Clin Pharmacol Ther; 1974 Mar; 15(3):276-82. PubMed ID: 4815953
    [No Abstract]   [Full Text] [Related]  

  • 18. Variations of serum diphenylhydantoin concentrations in epileptic out-patients.
    Vapaatalo H; Lehtinen L
    Eur Neurol; 1971; 5(5):303-10. PubMed ID: 5133553
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical pharmacokinetics of phenytoin in the dog: a reevaluation.
    Frey HH; Löscher W
    Am J Vet Res; 1980 Oct; 41(10):1635-8. PubMed ID: 6784613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of phenytoin from various pharmaceutical preparations in children.
    Manson JI; Beal SM; Magarey A; Pollard AC; O'Reilly WJ; Sansom LN
    Med J Aust; 1975 Oct; 2(15):590-2. PubMed ID: 1196223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.